

S1 Table. Patient and tumor characteristics of the two clear cell RCC cohorts

Variable	TCGA KIRC cohort	Severance hospital cohort
No. of samples	534	143
Median age (yr)	61	60
Sex		
Male	346	103
Female	188	40
WHO/ISUP nuclear grade ^{a)}		
1	14	
2	229	25
3	207	79
4	76	39
Pathologic tumor stage		
pT1	274	
pT2	69	
pT3	180	139
pT4	11	4
Adjuvant treatment		
None	N/A	66
VEGFR-TKI	N/A	67
Others	N/A	10
FPN mRNA level		
Low	267	N/A
High	267	N/A
FPN IHC expression		
Low	N/A	71
High	N/A	72
FBXL5 mRNA level		
Low	267	N/A
High	267	N/A
FBXL5 IHC expression		
Low	N/A	85
High	N/A	58
Recurrence/Metastasis ^{b)}		
Absent	309	54
Present	127	89
Survival status		
Alive	359	86
Expired	175	57

FBXL5, F-box and leucine rich repeat protein 5; FPN, ferroportin; KIRC, kidney renal clear cell carcinoma; RCC, renal cell carcinoma; TCGA, The Cancer Genome Atlas; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor. ^{a)}Nuclear grade for TCGA KIRC cohort was available in 526 cases, ^{b)}Recurrence or distant metastasis data for TCGA KIRC cohort was available in 436 cases.